The lateral flow immunoassay (lfia) based rapid test market size has grown steadily in recent years. It will grow from $7.17 billion in 2025 to $7.31 billion in 2026 at a compound annual growth rate (CAGR) of 2%. The growth in the historic period can be attributed to expansion of rapid infectious disease screening, increasing adoption of pregnancy and fertility tests, growth of point-of-care diagnostics, availability of low-cost rapid tests, rising public health screening initiatives.
The lateral flow immunoassay (lfia) based rapid test market size is expected to see steady growth in the next few years. It will grow to $8.67 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing investments in decentralized diagnostics, expansion of self-testing applications, growing demand for rapid cardiac and toxicology tests, rising integration with digital health platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing demand for rapid immunoassay-based testing, rising adoption of home-use lfia kits, growing use of multiplex detection assays, expansion of infectious disease testing applications, enhanced focus on user-friendly test design.
The rising prevalence of chronic diseases is expected to drive growth in the lateral flow immunoassay (LFIA) based rapid test market. Chronic diseases, also referred to as non-communicable diseases (NCDs), are long-term health conditions that persist over extended periods, often throughout a person’s lifetime. LFIA-based rapid tests facilitate early detection, point-of-care testing, rapid results, ongoing monitoring, and reduced healthcare costs associated with chronic disease management. These tests are valued for providing quick and accessible results, allowing healthcare professionals and patients to make timely decisions regarding treatment and lifestyle adjustments. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported that 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. As a result, the growing prevalence of chronic diseases is supporting the expansion of the LFIA-based rapid test market.
Companies in the market are focusing on advanced diagnostic technologies to improve efficiency and patient care. Integrated Health Solutions, for instance, connect healthcare services, technologies, and data to enhance workflow and collaboration across healthcare platforms. In June 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, launched analytical units for its Cobas Pro integrated solutions. The system can process up to 1,000 samples per hour using its sample supply unit and perform up to 900 tests per hour for ion-selective electrode (ISE) analysis and 1,000 tests per hour on the Cobas C 503 unit for clinical chemistry, streamlining laboratory operations and improving patient care.
In August 2023, Danaher Corporation, a US-based medical products company, acquired Abcam plc for $5.7 billion. This acquisition aligns with Danaher’s strategy to expand its life sciences business and support clients in addressing major healthcare challenges. Abcam plc, a UK-based biotechnology company, specializes in the manufacture of LFIA-based rapid tests, and the acquisition is expected to enhance value for shareholders while delivering improved outcomes for employees and clients.
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., PerkinElmer Inc., Hologic Inc., LTEK Co. Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd, Qiagen N.V., Merck KGaA, 3a Diagnostics, Roche Holding AG, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, CTK Biotech.
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lateral flow immunoassay (lfia) based rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the LFIA based rapid test market by increasing costs of imported antibodies, membranes, nanoparticles, reader components, and packaging materials. Healthcare systems and diagnostic manufacturers in North America and Europe are most affected due to reliance on imported raw materials, while Asia-Pacific faces cost pressure on large-scale test production. These tariffs are increasing unit costs and affecting affordability. At the same time, they are driving domestic manufacturing, local sourcing of assay components, and innovation in cost-efficient rapid test formats.
The lateral flow immunoassay (lfia) based rapid test market research report is one of a series of new reports that provides lateral flow immunoassay (lfia) based rapid test market statistics, including lateral flow immunoassay (lfia) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (lfia) based rapid test market share, detailed lateral flow immunoassay (lfia) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (lfia) based rapid test industry. This lateral flow immunoassay (lfia) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The rapid test based on Lateral Flow Immunoassay (LFIA) is a straightforward technology-driven diagnostic device employed for detecting the presence of specific targets, such as pathogens or biomarkers, in samples obtained from the human body. These samples encompass various bodily fluids such as urine, saliva, blood, and sweat.
The primary techniques include the competitive assay, sandwich assay, and multiplex detection assay. The competitive assay specifically determines the presence of targets, such as pathogens or biomarkers, within the collected samples. Its applications span infectious diseases, pregnancy and fertility assessments, toxicology, and others, making it applicable in diverse settings such as hospitals, clinics, diagnostic laboratories, home care, and more.
Lateral Flow Immunoassay (LFIA) based rapid test market consists of sales of conjugate pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The lateral flow immunoassay (lfia) based rapid test market size is expected to see steady growth in the next few years. It will grow to $8.67 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing investments in decentralized diagnostics, expansion of self-testing applications, growing demand for rapid cardiac and toxicology tests, rising integration with digital health platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing demand for rapid immunoassay-based testing, rising adoption of home-use lfia kits, growing use of multiplex detection assays, expansion of infectious disease testing applications, enhanced focus on user-friendly test design.
The rising prevalence of chronic diseases is expected to drive growth in the lateral flow immunoassay (LFIA) based rapid test market. Chronic diseases, also referred to as non-communicable diseases (NCDs), are long-term health conditions that persist over extended periods, often throughout a person’s lifetime. LFIA-based rapid tests facilitate early detection, point-of-care testing, rapid results, ongoing monitoring, and reduced healthcare costs associated with chronic disease management. These tests are valued for providing quick and accessible results, allowing healthcare professionals and patients to make timely decisions regarding treatment and lifestyle adjustments. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported that 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. As a result, the growing prevalence of chronic diseases is supporting the expansion of the LFIA-based rapid test market.
Companies in the market are focusing on advanced diagnostic technologies to improve efficiency and patient care. Integrated Health Solutions, for instance, connect healthcare services, technologies, and data to enhance workflow and collaboration across healthcare platforms. In June 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, launched analytical units for its Cobas Pro integrated solutions. The system can process up to 1,000 samples per hour using its sample supply unit and perform up to 900 tests per hour for ion-selective electrode (ISE) analysis and 1,000 tests per hour on the Cobas C 503 unit for clinical chemistry, streamlining laboratory operations and improving patient care.
In August 2023, Danaher Corporation, a US-based medical products company, acquired Abcam plc for $5.7 billion. This acquisition aligns with Danaher’s strategy to expand its life sciences business and support clients in addressing major healthcare challenges. Abcam plc, a UK-based biotechnology company, specializes in the manufacture of LFIA-based rapid tests, and the acquisition is expected to enhance value for shareholders while delivering improved outcomes for employees and clients.
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., PerkinElmer Inc., Hologic Inc., LTEK Co. Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd, Qiagen N.V., Merck KGaA, 3a Diagnostics, Roche Holding AG, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, CTK Biotech.
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lateral flow immunoassay (lfia) based rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the LFIA based rapid test market by increasing costs of imported antibodies, membranes, nanoparticles, reader components, and packaging materials. Healthcare systems and diagnostic manufacturers in North America and Europe are most affected due to reliance on imported raw materials, while Asia-Pacific faces cost pressure on large-scale test production. These tariffs are increasing unit costs and affecting affordability. At the same time, they are driving domestic manufacturing, local sourcing of assay components, and innovation in cost-efficient rapid test formats.
The lateral flow immunoassay (lfia) based rapid test market research report is one of a series of new reports that provides lateral flow immunoassay (lfia) based rapid test market statistics, including lateral flow immunoassay (lfia) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (lfia) based rapid test market share, detailed lateral flow immunoassay (lfia) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (lfia) based rapid test industry. This lateral flow immunoassay (lfia) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The rapid test based on Lateral Flow Immunoassay (LFIA) is a straightforward technology-driven diagnostic device employed for detecting the presence of specific targets, such as pathogens or biomarkers, in samples obtained from the human body. These samples encompass various bodily fluids such as urine, saliva, blood, and sweat.
The primary techniques include the competitive assay, sandwich assay, and multiplex detection assay. The competitive assay specifically determines the presence of targets, such as pathogens or biomarkers, within the collected samples. Its applications span infectious diseases, pregnancy and fertility assessments, toxicology, and others, making it applicable in diverse settings such as hospitals, clinics, diagnostic laboratories, home care, and more.
Lateral Flow Immunoassay (LFIA) based rapid test market consists of sales of conjugate pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Characteristics
3. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Supply Chain Analysis
4. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Trends and Strategies
5. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Analysis of End Use Industries
7. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Total Addressable Market (TAM) Analysis for the Market
9. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Segmentation
10. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Regional and Country Analysis
11. Asia-Pacific Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
12. China Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
13. India Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
14. Japan Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
15. Australia Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
16. Indonesia Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
17. South Korea Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
18. Taiwan Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
19. South East Asia Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
20. Western Europe Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
21. UK Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
22. Germany Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
23. France Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
24. Italy Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
25. Spain Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
26. Eastern Europe Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
27. Russia Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
28. North America Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
29. USA Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
30. Canada Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
31. South America Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
32. Brazil Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
33. Middle East Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
34. Africa Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
36. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Competitive Landscape and Company Profiles
37. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Other Major and Innovative Companies
40. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses lateral flow immunoassay (lfia) based rapid test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for lateral flow immunoassay (lfia) based rapid test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lateral flow immunoassay (lfia) based rapid test market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technique: Competitive Assay; Sandwich Assay; Multiplex Detection Assay2) By Application: Infectious Disease; Pregnancy And Fertility; Toxicology; Cardiac Marker And Cholesterol Testing; Other Applications
3) By End-Users: Hospitals And Clinics; Diagnostic Laboratories; Home Care; Other End Users
Subsegments:
1) By Competitive Assay: Direct Competitive Assays; Indirect Competitive Assays2) By Sandwich Assay: Single-step Sandwich Assays; Two-step Sandwich Assays
3) By Multiplex Detection Assay: Multi-analyte Assays; Simultaneous Detection Of Various Targets
Companies Mentioned: Abbott Laboratories; F. Hoffmann-La Roche; Quidel Corporation; Becton Dickinson and Company; Danaher Corporation; Thermo Fisher Scientific Inc.; Bio-Rad Laboratories Inc.; PerkinElmer Inc.; Hologic Inc.; LTEK Co. Ltd.; JOYSBIO Biotechnology; Jiangsu Medomics Medical Technologies; Diagnocure; Ubio Biotechnology Systems; Elabscience® Immunoassay Kits; FyoniBio / Glycotope GmbH; Atomo Diagnostics Limited; INDICAL Bioscience; Lionex Gmbh; BIOMED Labordiagnostik GmbH; EKF Diagnostics; Launch Diagnostics; Diagnostic Instruments Ltd; Qiagen N.V.; Merck KGaA; 3a Diagnostics; Roche Holding AG; Biomaxima; SensDx; Vitrosens Biotechnology; Bioeasy Biotechnology; Fujirebio; Immunodiagnostic Systems Holdings PLC; Mesa Biotech Inc; CTK Biotech
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Lateral Flow Immunoassay (LFIA) Based Rapid Test market report include:- Abbott Laboratories
- F. Hoffmann-La Roche
- Quidel Corporation
- Becton Dickinson and Company
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- PerkinElmer Inc.
- Hologic Inc.
- LTEK Co. Ltd.
- JOYSBIO Biotechnology
- Jiangsu Medomics Medical Technologies
- Diagnocure
- Ubio Biotechnology Systems
- Elabscience® Immunoassay Kits
- FyoniBio / Glycotope GmbH
- Atomo Diagnostics Limited
- INDICAL Bioscience
- Lionex Gmbh
- BIOMED Labordiagnostik GmbH
- EKF Diagnostics
- Launch Diagnostics
- Diagnostic Instruments Ltd
- Qiagen N.V.
- Merck KGaA
- 3a Diagnostics
- Roche Holding AG
- Biomaxima
- SensDx
- Vitrosens Biotechnology
- Bioeasy Biotechnology
- Fujirebio
- Immunodiagnostic Systems Holdings PLC
- Mesa Biotech Inc
- CTK Biotech
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.31 Billion |
| Forecasted Market Value ( USD | $ 8.67 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 35 |
